Stock Research: Pfizer

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Pfizer

NYQ:PFE US7170811035
32
  • Value
    98
  • Growth
    28
  • Safety
    Safety
    57
  • Combined
    75
  • Sentiment
    15
  • 360° View
    360° View
    32
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. It operates in the oncology, primary care, and specialty care industries. Pfizer operates globally with a focus on the U.S. and international markets. In the last fiscal year, the company had a market cap of $139,917 million, profits of $47,295 million, revenue of $63,627 million, and 81000 employees.

more

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Pfizer are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Pfizer. The consolidated Value Rank has an attractive rank of 98, which means that the share price of Pfizer is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 98% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 57. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 15. Professional investors are more confident in 85% other stocks. The consolidated Growth Rank also has a low rank of 28, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 72 of its competitors have better growth. ...read more

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 96 96 99
Growth
28 11 1 89
Safety
Safety
57 33 91 41
Sentiment
15 48 14 44
360° View
360° View
32 86 51 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
5 18 15 27
Opinions Change
68 65 17 40
Pro Holdings
n/a 32 61 43
Market Pulse
4 79 41 82
Sentiment
15 48 14 44
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 96 96 99
Growth
28 11 1 89
Safety Safety
57 33 91 41
Combined
75 77 81 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
77 47 37 46
Price vs. Earnings (P/E)
23 76 68 93
Price vs. Book (P/B)
75 54 50 31
Dividend Yield
100 100 100 100
Value
98 96 96 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
30 22 28 61
Profit Growth
96 18 13 84
Capital Growth
12 21 19 25
Stock Returns
28 47 19 97
Growth
28 11 1 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
28 42 62 52
Refinancing
51 11 63 15
Liquidity
82 73 91 75
Safety Safety
57 33 91 41

Similar Stocks

Discover high‑ranked alternatives to Pfizer and broaden your portfolio horizons.

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: